Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Operating Income: 2009-2025

Historic Operating Income for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to -$166.8 million.

  • Cytokinetics' Operating Income fell 18.43% to -$166.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$572.9 million, marking a year-over-year decrease of 9.21%. This contributed to the annual value of -$536.2 million for FY2024, which is 8.07% down from last year.
  • As of Q3 2025, Cytokinetics' Operating Income stood at -$166.8 million, which was down 49.55% from -$111.5 million recorded in Q2 2025.
  • Cytokinetics' Operating Income's 5-year high stood at -$10.9 million during Q2 2022, with a 5-year trough of -$166.8 million in Q3 2025.
  • For the 3-year period, Cytokinetics' Operating Income averaged around -$133.3 million, with its median value being -$127.4 million (2023).
  • Per our database at Business Quant, Cytokinetics' Operating Income plummeted by 1,434.90% in 2021 and then spiked by 80.16% in 2022.
  • Cytokinetics' Operating Income (Quarterly) stood at -$21.7 million in 2021, then crashed by 485.28% to -$127.0 million in 2022, then dropped by 0.31% to -$127.4 million in 2023, then decreased by 9.12% to -$139.0 million in 2024, then declined by 18.43% to -$166.8 million in 2025.
  • Its Operating Income was -$166.8 million in Q3 2025, compared to -$111.5 million in Q2 2025 and -$155.6 million in Q1 2025.